Wuhan Hiteck Biological Pharma Co Ltd. Stock Analysis 300683.SZ

Wuhan Hiteck Biological Pharma Co., Ltd. engages in the research, development, production, and sale of chemicals including biological products and thrombin. The company is headquartered in Wuhan, Hubei. The company went IPO on 2017-08-08. The firm operates its businesses through five segments. The Biopharmaceutical segment focuses on research and development, production, and sales of biological products. The Pharmaceutical Technology Services segment engages in the technical development, consulting, and transfer of chemical drugs. The In Vitro Diagnostic Reagents segment engages in research, development, production, and sales of in vitro diagnostic reagents. The Active Pharmaceutical Ingredients and Pharmaceutical Intermediates Production and Sales segment engages in the production, sales, and services of pharmaceutical intermediates and active pharmaceutical ingredients. The Others segment engages in the sales of traditional Chinese medicinal herbs and the wholesale and retail of health products. The firm mainly conducts its business in the domestic market.